↓ Skip to main content

Dove Medical Press

Article Metrics

Asenapine for bipolar disorder

Overview of attention for article published in Neuropsychiatric Disease and Treatment, December 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter
8 tweeters
facebook
2 Facebook pages
wikipedia
1 Wikipedia page

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
52 Mendeley
Title
Asenapine for bipolar disorder
Published in
Neuropsychiatric Disease and Treatment, December 2015
DOI 10.2147/ndt.s78043
Pubmed ID
Authors

Martha Sajatovic, Thomas Scheidemantel, Irina Korobkova, Soham Rej

Abstract

Asenapine (Saphris(®)) is an atypical antipsychotic drug which has been approved by the US Food and Drug Administration for the treatment of schizophrenia in adults, as well as the treatment of acute manic or mixed episodes of bipolar I in both adult and pediatric populations. Asenapine is a tetracyclic drug with antidopaminergic and antiserotonergic activity with a unique sublingual route of administration. In this review, we examine and summarize the available literature on the safety, efficacy, and tolerability of asenapine in the treatment of bipolar disorder (BD). Data from randomized, double-blind trials comparing asenapine to placebo or olanzapine in the treatment of acute manic or mixed episodes showed asenapine to be an effective monotherapy treatment in clinical settings; asenapine outperformed placebo and showed noninferior performance to olanzapine based on improvement in the Young Mania Rating Scale scores. There are limited data available on the use of asenapine in the treatment of depressive symptoms of BD, or in the maintenance phase of BD. The available data are inconclusive, suggesting the need for more robust data from prospective trials in these clinical domains. The most commonly reported adverse effect associated with use of asenapine is somnolence. However, the somnolence associated with asenapine use did not cause significant rates of discontinuation. While asenapine was associated with weight gain when compared to placebo, it appeared to be modest when compared to other atypical antipsychotics, and its propensity to cause increases in hemoglobin A1c or serum lipid levels appeared to be similarly modest. Asenapine does not appear to cause any clinically significant QTc prolongation. The most commonly reported extra-pyramidal symptom associated with asenapine was akathisia. Overall, asenapine appears to be a relatively well-tolerated atypical antipsychotic, effective in the treatment of acute manic and mixed episodes of BD.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 2%
United States 1 2%
Unknown 50 96%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 12 23%
Researcher 9 17%
Unspecified 7 13%
Other 7 13%
Student > Master 5 10%
Other 12 23%
Readers by discipline Count As %
Medicine and Dentistry 23 44%
Unspecified 10 19%
Psychology 6 12%
Nursing and Health Professions 6 12%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Other 5 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2019.
All research outputs
#1,898,846
of 12,858,563 outputs
Outputs from Neuropsychiatric Disease and Treatment
#289
of 2,172 outputs
Outputs of similar age
#57,390
of 350,448 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#13
of 72 outputs
Altmetric has tracked 12,858,563 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,172 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,448 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 72 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.